Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes (Start)

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: biphasic insulin aspart 30

Study type: Observational

Funder types: Industry

Identifiers

NCT01486875

BIASP-1721

Details and patient eligibility

About

This trial is conducted in Europe. The aim of this trial is to evaluate the incidence of serious adverse drug reactions when initiating insulin therapy with NovoMix® 30 in subjects with type 2 diabetes mellitus under normal clinical practice conditions in Sweden.

Enrollment: 1,155 patients

Sex: All

Ages: 18 to 68 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Subjects with type 2 diabetes

Trial design

1,155 participants in 1 patient group

BIAsp 30

Treatment:

Drug: biphasic insulin aspart 30